UroGen Historical Cash Flow
| URGN Stock | USD 12.70 0.04 0.32% |
Analysis of UroGen Pharma cash flow over time is an excellent tool to project UroGen Pharma future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Sale Purchase Of Stock of 1.5 M or Change In Cash of 41.6 M as it is a great indicator of UroGen Pharma ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining UroGen Pharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether UroGen Pharma is a good buy for the upcoming year.
UroGen |
About UroGen Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in UroGen balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which UroGen's non-liquid assets can be easily converted into cash.
UroGen Pharma Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by UroGen Pharma to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of UroGen Pharma operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from UroGen Pharma's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into UroGen Pharma current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.At this time, UroGen Pharma's Change To Netincome is very stable compared to the past year. As of the 1st of December 2024, Change To Liabilities is likely to grow to about 1.7 M, while Sale Purchase Of Stock is likely to drop about 1.5 M.
UroGen Pharma cash flow statement Correlations
Click cells to compare fundamentals
UroGen Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
UroGen Pharma cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Sale Purchase Of Stock | 165.3M | 16.5M | (83K) | 1.4M | 1.6M | 1.5M | |
| Change In Cash | (51.4M) | 3.9M | (8.5M) | 10.6M | 39.6M | 41.6M | |
| Stock Based Compensation | 30.0M | 28.0M | 23.1M | 10.6M | 9.3M | 14.1M | |
| Free Cash Flow | (71.3M) | (107.1M) | (85.6M) | (87.8M) | (76.6M) | (72.7M) | |
| Change In Working Capital | 4.3M | (6.4M) | (13.1M) | (6.3M) | 3.3M | 3.5M | |
| Begin Period Cash Flow | 101.6M | 50.2M | 54.1M | 45.6M | 56.2M | 39.3M | |
| Total Cashflows From Investing Activities | (145.6M) | 93.2M | 4.1M | 1.1M | 1.2M | 1.3M | |
| Other Cashflows From Financing Activities | 165.3M | 674K | 72.3M | 1.4M | 49.6M | 32.1M | |
| Depreciation | 1.3M | 2.0M | 1.8M | 1.8M | 1.7M | 966.1K | |
| Other Non Cash Items | (910K) | (1.5M) | (1.2M) | 16.1M | 11.5M | 12.1M | |
| Capital Expenditures | 325K | 1.2M | 752K | 254K | 194K | 184.3K | |
| Total Cash From Operating Activities | (71.0M) | (105.9M) | (84.9M) | (87.6M) | (76.4M) | (72.6M) | |
| Change To Operating Activities | 3.3M | 1.4M | 513K | (7.7M) | (6.9M) | (6.6M) | |
| Net Income | (105.1M) | (128.5M) | (110.8M) | (109.8M) | (102.2M) | (97.1M) | |
| Total Cash From Financing Activities | 165.3M | 16.5M | 72.3M | 97.1M | 116.9M | 62.6M | |
| End Period Cash Flow | 50.2M | 54.1M | 45.6M | 56.2M | 95.8M | 48.7M | |
| Change To Netincome | 30.0M | 26.9M | 23.1M | 11.5M | 13.2M | 15.3M | |
| Change To Liabilities | 4.7M | (1.2M) | (561K) | 887K | 1.0M | 1.7M | |
| Investments | (145.1M) | 94.5M | 4.8M | 1.3M | 33.5M | 35.2M | |
| Cash And Cash Equivalents Changes | (51.4M) | 3.9M | (8.5M) | 10.6M | 9.6M | 10.1M | |
| Cash Flows Other Operating | (276K) | 474K | 9.6M | 9.1M | 10.4M | 10.9M |
Pair Trading with UroGen Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if UroGen Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in UroGen Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against UroGen Stock
| 0.71 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.7 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.68 | BHC | Bausch Health Companies | PairCorr |
| 0.67 | GILD | Gilead Sciences | PairCorr |
| 0.56 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
The ability to find closely correlated positions to UroGen Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace UroGen Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back UroGen Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling UroGen Pharma to buy it.
The correlation of UroGen Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as UroGen Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if UroGen Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for UroGen Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.02) | Revenue Per Share 2.389 | Quarterly Revenue Growth 0.209 | Return On Assets (0.21) | Return On Equity (14.81) |
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.